Compare Kohl's Corporation (KSS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Twist Bioscience Corp — how do they compare? Kohl's Corporation trades at $17.41 (market cap $1.99B), while Twist Bioscience Corp trades at $88.43 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 2.7× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.85% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| KSS | TWST | |
|---|---|---|
Market Cap | $1.99B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $102.88 |
52-Week Low | $10.42 | $24.16 |
Enterprise Value | $8.10B | $5.37B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $17.59, up 1.68% on the day, with a bullish technical signal from moving averages. The stock shows deep value metrics with a P/E of 7.27 and P/B of 0.49, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal operational improvements. Cash flow turned positive in 2026 projections at $276M, and the company is focusing on proprietary brands and value initiatives to drive traffic.
Outlook: Turnaround efforts under CEO Michael Bender show early progress, but revenue declines persist. Investment case hinges on margin expansion and market share recovery. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analyst consensus is mixed with a $16.75 price target below current levels, suggesting cautious optimism amid execution uncertainty.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
